Medarex strengthening monoclonal antibody program with GenPharm, HBI acquisitions.
Executive Summary
MEDAREX GENPHARM ACQUISITION TO BOLSTER MONOCLONAL ANTIBODY PROGRAM, Baltimore-based biotech Medarex reported May 6. "Through this acquisition, Medarex will expand its business and technology base to include GenPharm's patented HuMab-Mouse, an antibody discovery platform that complements Medarex's patented Bispecific antibody technology," the company said.